Attached files

file filename
EX-31.1 - CERTIFICATION BY MARTIN A. MATTINGLY AS CEO - SYNAGEVA BIOPHARMA CORPdex311.htm
EX-23.2 - CONSENT OF KPMG LLP - SYNAGEVA BIOPHARMA CORPdex232.htm
EX-32.2 - SECTION 1350 CERTIFICATION BY ANDREW L. GRAHAM AS CFO - SYNAGEVA BIOPHARMA CORPdex322.htm
EX-31.2 - CERTIFICATION BY ANDREW L. GRAHAM AS CFO - SYNAGEVA BIOPHARMA CORPdex312.htm
10-K - FORM 10-K - SYNAGEVA BIOPHARMA CORPd10k.htm
EX-23.1 - CONSENT OF ERNST AND YOUNG LLP - SYNAGEVA BIOPHARMA CORPdex231.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of Trimeris, Inc. (the “Company”) for the period ended December 31, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Martin Mattingly, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ MARTIN A. MATTINGLY

Martin A. Mattingly
Chief Executive Officer
March 16, 2010

 

The foregoing certification is being furnished solely pursuant to § 18 U.S.C. 1350 and is not being filed as part of the Report or as a separate disclosure document.